A few years ago, many companies threw in the towel on neurological diseases because poor understanding of their biology made R&D too risky. The field is finally receiving increased private and public funding, but some …

The National Cancer Institute has created a generous seven-year award designed to ease the grant-writing burden for 'outstanding investigators'. Now the institute needs to ensure that the program is not just easier …

AstraZeneca has unveiled plans for its R&D center and global headquarters in Cambridge, U.K. -- the next major step in the pharma's strategy to improve pipeline productivity to help it recover growth and regain ground …

Translational Notes: AD mission in the U.K. Table 1. Dementia public-private partnerships. Selected public-private partnerships focused on dementia research initiated over the past five years. Date Title Companies…

Translational Notes: AD mission in the U.K. Table 2. Dementia research initiatives in the U.K. Select U.K.-based dementia research initiatives launched during the past year. Alzheimer's Research UK is contributing a …

The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly L120 million (US $205 million) from U.K.-based organizations for a series of research initiatives spanning discovery to the …

The Quebec Consortium for Drug Discovery and Brain Canada have announced at least C$10 million (US$9.2 million) in funding for a new program to develop tools for pharma partners to accelerate the discovery of …

The FDA's first two centers for regulatory sciences were focused on modernizing methods and building bridges to academia. The agency now is at earlier drug development and has partnered with Stanford and UCSF to create …

The Sanford-Burnham Medical Research Institute has been seeking broader industrial partnerships that tap both its basic research and drug discovery expertise. Its new deal with Daiichi is the most expansive of its four …

As the Structural Genomics Consortium enters its second decade, SciBX spoke with Aled Edwards about how the open-access business model has evolved globally and the organization's plans to engage clinician scientists and…

New York has long been a producer of top science but has struggled to retain and develop its own innovations. Now, with a flurry of activities aiming to establish it as a biotech hub, New York's next task is to persuade…

NIAID has awarded a 5-year, $26 million grant for antibiotic development that brings together researchers from Rutgers University, Rockefeller University and Cubist. The goal is to take discovery-stage programs through …

Temple University has teamed up with MorphoSys to bring industry-quality antibody discovery capabilities in-house. The partnership complements the university's medicinal chemistry expertise while expanding the company's…